Brief: Nuvation Bio Secures Up To $250 Million In Non-Dilutive Financings From Sagard Healthcare Partners
03/03/2025 14:25
March 3 (Reuters) - Nuvation Bio Inc NUVB.N: NUVATION BIO SECURES UP TO $250 MILLION IN NON-DILUTIVE FINANCINGS FROM SAGARD HEALTHCARE PARTNERS NUVATION BIO INC: PROCEEDS FROM ROYALTY INTEREST FINANCING EXPECTED TO FULLY FUND U.S. COMMERCIAL LAUNCH OF TALETRECTINIB Source text: ID:nBw5gXy34a Further company coverage: NUVB.N (Reuters.Briefs@thomsonreuters.com)
Recent news on Nuvation Bio
See all newsBrief: Nuvation Bio To Expand Pivotal Phase 3 Sigma Study Of Safusidenib For Idh1-Mutant Glioma To Six European Countries
Brief: Nuvation Bio To Report Third Quarter 2026 Financial Results And Provide Business Update On November 4, 2026
U.S. RESEARCH ROUNDUP-Everpure, Marvell Technology, Okta
Nuvation Bio Inc. reports results for the quarter ended June 30 - Earnings Summary
Nuvation Bio Q2 revenue beats estimates on IBTROZI growth